Physician profile
Muhammad Naeem
NPI 1710186291
$1,459.33
in general payments reported to CMS, 2019-2025
23 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $204 · 2024: $141 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $188.55 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $156.94 | 2019-2020 | |
| Lilly USA, LLC | $151.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $143.06 | 2019-2020 | |
| Pfizer INC. | $120.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.36 | 2019-2020 | |
| Amgen INC. | $80.29 | 2019 | |
| Astellas Pharma US INC | $78.85 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $59.96 | 2019-2020 | |
| Glaxosmithkline, LLC. | $56.18 | 2024-2025 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $44.09 | 2024-2025 | Gemtesa |
| Melinta Therapeutics, LLC | $31.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.81 | 2019 | |
| Lundbeck LLC | $28.63 | 2025 | Vyepti |
| Sk Life Science, INC. | $28.29 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $25.09 | 2025 | Aristada, Lybalvi |
| Merck Sharp & Dohme LLC | $22.71 | 2019 | |
| Exact Sciences Corporation | $22.00 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.05 | 2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $16.97 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.00 | 2025 | Voquezna |
| Avanir Pharmaceuticals, INC. | $14.03 | 2019 | |
| Sanofi Pasteur INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Naeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.